All GLP-1 medications discussed in this guide — including liraglutide, semaglutide, and tirzepatide — require a valid prescription from a licensed healthcare provider. Nothing in this guide constitutes medical advice or a recommendation to change or initiate any medication. Consult a qualified physician before making any changes to your treatment.
The Prescription Wording Effect: How Four Words Change Your Bill
Moderate — Well-documented pricing structure; NDC-based pharmacy pricing is established practiceThe US pharmaceutical pricing system does not price drugs. It prices specific National Drug Codes — NDCs — which identify a particular drug, manufacturer, dose, and formulation as a unique product. From the insurer's and pharmacy's perspective, “Saxenda 1.2mg” and “liraglutide 1.2mg” and “Victoza 1.2mg” are three different NDCs with three potentially different prices, coverage tiers, and prior authorization requirements, even though they can refer to the same molecule at the same dose.
This matters practically because what your prescriber writes on the prescription — specifically which brand name or generic name they use, and which indication they document — determines which NDC gets submitted to your pharmacy and insurer. A physician writing “Saxenda” and a physician writing “liraglutide” for the same patient condition may generate very different out-of-pocket costs for that patient, even before insurance enters the calculation. The prescription wording effect has four main levers:
The Four Levers of Prescription Wording Cost
1. The Indication on the Prescription
Insurance companies cover medications differently depending on the documented indication. A GLP-1 medication prescribed for type 2 diabetes may be covered under your pharmacy benefit or medical benefit at a different tier than the same drug prescribed for obesity. Some insurers cover diabetes medications broadly and obesity medications narrowly or not at all. The indication your prescriber documents — and communicates to the pharmacy and insurer — is the first and often most consequential wording lever.
2. Brand Name vs. Generic Name
When a prescriber writes a brand name (e.g., “Saxenda”), the pharmacy dispenses that brand product unless the prescriber has authorized substitution. When a prescriber writes the generic name (“liraglutide”), the pharmacy can substitute a generic equivalent. For drugs where multiple generic manufacturers have entered the market, this can be a substantial price difference. For drugs that remain under patent protection with no approved generic, this lever has no effect — there is no cheaper generic to substitute.
3. The Dose Specified
Different doses of the same drug can have very different prices. This is not linear: a 2mg dose does not always cost twice a 1mg dose, and pen sizes, pen quantities, and pharmacy acquisition costs all factor in. If a patient is using a lower dose than the maximum approved — for example, using liraglutide at 1.2mg rather than 1.8mg or 3mg — specifying the correct dose on the prescription avoids being dispensed the higher-cost higher-dose presentation unnecessarily.
4. What Your Insurance Covers for Each Indication
Insurance formularies are indication-specific. A drug covered at Tier 2 for one indication may be Tier 4 or non-covered for another. For GLP-1 medications, many commercial insurers cover semaglutide and liraglutide for type 2 diabetes more readily than for obesity, reflecting both historical formulary structures and the fact that obesity coverage mandates are less uniform than diabetes coverage mandates. Understanding your specific plan's formulary before the prescription is written — rather than after the pharmacy bills you — gives you the information to have a productive conversation with your prescriber about which indication documentation is most appropriate and most economical.
Understanding these levers gives patients actionable leverage in what is otherwise an opaque system. Most patients receive a prescription, present it to a pharmacy, and pay whatever the pharmacy charges without knowing that alternative wording or alternative pharmacies could produce a dramatically different bill. This guide explains how to use that information without crossing the line into misrepresenting a diagnosis — which is fraud and which this guide explicitly does not recommend.
The cost-reduction strategies described in this guide are limited to legitimate approaches: using the correct generic name, documenting accurate diagnoses, using price comparison tools, and applying for programs you qualify for. Misrepresenting a diagnosis you do not have in order to access lower-cost coverage is insurance fraud. This guide does not recommend that, and the examples given below are explicitly framed around situations where both diagnoses are medically accurate and documented.
Victoza vs. Saxenda: The Same Molecule, Two Price Tags
Strong — Established market facts; liraglutide is a well-characterized generic with documented price differences by indicationLiraglutide is the clearest real-world example of the prescription wording effect in the GLP-1 class. Novo Nordisk markets it under two brand names for two indications: Victoza (approved for type 2 diabetes management, at doses up to 1.8mg daily) and Saxenda (approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity, at doses up to 3mg daily). The molecule is identical. The difference is the approved indication, the maximum approved dose, and consequently the NDC under which it is sold and covered.
The Dual-Diagnosis Opportunity
For patients who have both type 2 diabetes and obesity — a clinically common combination, since these conditions are strongly associated — the prescription wording effect creates a genuine cost-reduction opportunity. If your prescriber documents the diabetes indication for a liraglutide prescription, the prescription may access diabetes-indication pricing and coverage, which has historically been lower than the obesity indication for the same molecule. If both diagnoses are medically accurate and documented in your record, using the diabetes indication is not misrepresentation — it is selecting among accurate characterizations of your condition.
The scenario: A patient has documented type 2 diabetes (HbA1c above threshold, on diabetes management) and also meets criteria for obesity (BMI above 30, or above 27 with a weight-related comorbidity). The prescriber can accurately document either or both indications. If the diabetes indication produces lower cost or better coverage, and both diagnoses are medically accurate, prescribing liraglutide with the diabetes indication documented is clinically and legally appropriate.
What this is not: If a patient has obesity but does not have type 2 diabetes, documenting a diabetes indication to access diabetes pricing is misrepresentation of a diagnosis. That is insurance fraud. This guide does not recommend it. The dual-indication strategy applies only where both diagnoses are medically accurate and documented.
Before assuming that the diabetes indication produces lower cost, verify with your specific insurer. Formularies vary substantially between plans, and some plans have redesigned their GLP-1 coverage in ways that make the indication distinction less consequential. Check your plan's formulary, call your insurer's pharmacy benefit line, and ask specifically: what tier is liraglutide covered under for the diabetes indication, and what tier for the obesity indication? The conversation takes 10 minutes and may save hundreds of dollars per month.
If you have both documented type 2 diabetes and obesity: “I have both diagnoses. My insurance covers diabetes medications at a lower tier than obesity medications. Is it medically appropriate to document the diabetes indication for this prescription, and can you write it as generic liraglutide rather than Saxenda?” A physician who understands formulary dynamics should be able to engage with this question and, where clinically appropriate, accommodate it.
Generic Semaglutide: What to Expect and When
Preliminary — Patent and regulatory timelines are subject to change; compounding status subject to ongoing FDA guidanceSemaglutide is the active molecule in Ozempic (weekly injectable for type 2 diabetes), Wegovy (weekly injectable for obesity), and Rybelsus (daily oral tablet for type 2 diabetes). As of June 2026, no FDA-approved generic injectable semaglutide has reached the US market. This is primarily a patent protection issue: Novo Nordisk holds multiple overlapping patents on semaglutide products, and patent expiration timelines are both formulation-specific and subject to litigation.
The Patent Landscape as of June 2026
Novo Nordisk's patent protection on semaglutide is layered. The core compound patent, method-of-treatment patents, and formulation-specific patents (covering the specific pen device, the stabilizing excipients, and the release kinetics) create overlapping protection that extends into the late 2020s and early 2030s depending on the specific product formulation being challenged. Generic manufacturers seeking FDA approval through the Abbreviated New Drug Application (ANDA) process must either design around these patents, successfully challenge their validity through Paragraph IV certifications, or wait for them to expire. None of these paths have produced an approved US generic injectable semaglutide as of the date of this guide.
Patent expiration and potential generic entry timelines have been discussed in analyst reports in the range of 2026–2032, depending on which formulation and which patents are at issue. These are estimates subject to litigation outcomes and FDA processing timelines. BetterNewLives.com does not make specific predictions about generic entry dates. Monitor the FDA ANDA approval database and pharmaceutical trade press for updates.
Compounded Semaglutide: The Shortage Exception and Its Limits
During the period when branded semaglutide was on the FDA's drug shortage list, 503B outsourcing facilities (licensed compounding pharmacies that meet specific manufacturing standards) were permitted to compound semaglutide for dispensing. This created a parallel market for compounded semaglutide that was substantially less expensive than branded Ozempic or Wegovy. Many patients accessed GLP-1 therapy through this compounding channel during the shortage period at a fraction of the branded cost.
However, the FDA shortage designation is not permanent, and as Novo Nordisk has increased production capacity, the FDA has been reassessing the compounding allowance. As of mid-2026, the compounding allowance status has been actively evolving: the FDA issued guidance indicating that branded supply has recovered for certain strengths and formulations, which triggered questions about continued 503B compounding legality for those formulations. Patients and providers should check the current FDA shortage list and the most recent FDA guidance on compounding allowances before making decisions based on compounded semaglutide availability. The landscape has been changing on a quarterly basis.
The legal and regulatory status of compounded semaglutide has been in flux. Do not rely on guidance from even several months ago as current. Before accessing compounded semaglutide, verify: (1) the current FDA shortage list status for semaglutide; (2) current FDA guidance on 503B outsourcing facility compounding for semaglutide; (3) that the compounding pharmacy is a licensed 503B outsourcing facility or a licensed 503A compounding pharmacy with a valid patient-specific prescription. Non-licensed gray-market sources carry significant safety risks and are not legal. Consult a physician before making any changes based on compounding availability.
Canada: Oral Generic Semaglutide
Generic oral semaglutide (equivalent to Rybelsus, the daily tablet form approved for type 2 diabetes in the US) has become available in some Canadian provinces earlier than in the US. Canadian generic drug approval does not affect US market availability. Purchasing medications from Canadian sources for use in the US involves importation issues that are outside the scope of this guide. US patients cannot legally import prescription medications from Canada for personal use under current FDA policy (with narrow exceptions for specific circumstances), and this guide does not recommend attempting to do so. The Canadian generic oral semaglutide availability is noted here as context for understanding the global patent landscape, not as a purchasing recommendation.
For patients seeking lower-cost semaglutide options within the US legal framework, the most reliable near-term strategies are the manufacturer savings programs, insurance prior authorization, and pharmacy price comparison using tools like GoodRx — all covered in the sections below. Generic injectable semaglutide at competitive prices is not currently available and may not be for several years. Planning around that reality is more productive than waiting for a near-term generic entry that has not occurred.
For the most current information on semaglutide compounding status and generic entry: the FDA drug shortage database (accessdata.fda.gov), the FDA's compounding guidance page, and pharmaceutical trade publications covering ANDA filings. BetterNewLives.com will update this guide as the landscape changes.
How to Reduce Your GLP-1 Costs Legitimately
Moderate — Price comparison tools, generic substitution, and mail-order savings are well-documented; specific savings vary by plan and pharmacyThe GLP-1 pricing environment rewards patients who are willing to spend an hour researching their options before filling a prescription. The difference between what a patient pays at a retail pharmacy without comparison and what a patient pays after applying even a few of these strategies can be hundreds of dollars per month. None of these strategies require misrepresenting anything — they require information and a willingness to ask.
- Use GoodRx or a comparable price comparison tool (RxSaver, NeedyMeds) to check prices at multiple pharmacies before filling your prescription. For generic liraglutide in particular, price variation between pharmacies can be substantial — sometimes over $100 per month for the same drug and dose.
- Ask your prescriber to write the generic name (liraglutide, not Saxenda) when a generic is available and appropriate. Generic substitution is one of the most effective cost-reduction tools in the pharmacy benefit system and applies to any drug where an AB-rated generic exists.
- If you have both a diabetes diagnosis and an obesity diagnosis, ask your prescriber whether the diabetes indication can be documented for your prescription, and verify with your insurer whether that indication produces lower cost or better coverage under your specific plan.
- Ask about mail-order pharmacy. For maintenance medications taken long-term (which GLP-1 therapy typically is), mail-order pharmacies affiliated with your insurer typically offer a 20–30% cost reduction over retail pharmacy for a 90-day supply, plus the convenience of home delivery.
- Check whether the manufacturer offers a savings card for your specific drug. Novo Nordisk (NovoCare) and Eli Lilly have offered savings cards that cap patient monthly costs for commercially insured patients. See Section 6 for details.
- Ask your pharmacy about 90-day supply pricing. Filling 90 days at once rather than 30 days is typically less expensive on a per-dose basis, and it reduces the number of trips to the pharmacy.
- If you are currently using compounded semaglutide, verify the current legal and regulatory status (see Section 3) and compare the total cost against branded alternatives after applying any savings card or patient assistance for which you qualify. The cost differential may be smaller than you expect after applying legitimate manufacturer programs.
- If you have been denied coverage, read Section 5 on prior authorization appeal before giving up. A denied PA is the beginning of an appeal process, not a final answer.
Price Comparison Tools: How They Work
GoodRx, RxSaver, NeedyMeds, and similar services are price comparison and coupon aggregators. They negotiate discounted prices with participating pharmacies by aggregating volume, then pass those discounts to users through coupon codes. The discount is funded by the pharmacy agreeing to a lower margin in exchange for directing patients to their location. For generic drugs with multiple manufacturers in the market — including generic liraglutide — these tools can produce meaningful savings by identifying which participating pharmacy has the lowest acquisition cost for a specific NDC.
Important limitation: GoodRx coupons and insurance coverage are mutually exclusive at the pharmacy level. If you use a GoodRx coupon, the transaction does not run through your insurance, which means the amount does not count toward your deductible or out-of-pocket maximum. For patients who are close to meeting their deductible, running through insurance even at a higher cost may be the better financial decision. For patients who have a high deductible and are unlikely to meet it, GoodRx pricing is often lower than the insurance-negotiated price they would pay during the deductible phase. Do the math for your specific situation before deciding which route to use.
Run this comparison before every prescription fill: (1) What will your pharmacy charge running it through your insurance? (2) What does GoodRx show for the same drug and dose at your pharmacy and at the two or three nearest alternatives? (3) Has the manufacturer savings card changed terms since you last checked? The 15 minutes this comparison takes can save more per hour than most other financial activities you could do instead.
Insurance Prior Authorization Strategy
Moderate — Prior authorization criteria are plan-specific; appeal rights are established under federal and state lawPrior authorization (PA) is a process by which an insurer requires advance approval before covering a medication. For GLP-1 medications prescribed for obesity and weight management, PA is the rule rather than the exception: most commercial health plans require documentation of medical necessity before covering Wegovy, Ozempic for weight management, Saxenda, or Zepbound. Understanding how PA works — and how to appeal a denial effectively — is one of the highest-value things a GLP-1 patient or prospective patient can learn.
Typical Prior Authorization Criteria for GLP-1 Obesity Medications
While criteria vary by plan, the following are the most common requirements for PA approval of GLP-1 medications for obesity:
- BMI threshold: Most plans require a BMI of 30 or greater (obesity) or 27 or greater with at least one documented weight-related comorbidity. The comorbidities typically listed include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.
- Documented comorbidities: The comorbidity must be documented in your medical record, not just self-reported. Your prescriber needs to have recorded the diagnosis and ideally have supporting clinical data (A1C values, blood pressure readings, lipid panels, sleep study results).
- Prior treatment failure: Many plans require documentation that the patient has tried and failed to achieve adequate weight loss through a prior treatment — typically a structured lifestyle intervention program (supervised diet and exercise), and sometimes a prior weight loss medication at a lower cost tier. Step therapy requirements vary substantially between plans.
- Prescriber qualification: Some plans require the prescribing provider to be a physician (MD or DO) rather than a nurse practitioner or physician assistant, or to have a specific specialty. This is increasingly less common as telehealth prescribing has become mainstream, but it is worth checking.
If Your Prior Authorization Is Denied
A PA denial is not the end of the road. Under federal law and most state insurance regulations, you have the right to an internal appeal and, in most cases, an external appeal to an independent reviewer. The internal appeal must typically be decided within 30 days for non-urgent requests (15 days in many state regulations). External review by an independent organization not affiliated with your insurer must typically be decided within 45 days.
The strongest PA appeals include: a physician letter of medical necessity that specifically addresses the insurer's stated denial reason; your weight history showing the degree and chronicity of obesity; your comorbidity list with supporting clinical data from your medical record; documentation of any prior treatments you have attempted and their outcomes; and the specific clinical guideline the prescriber is following (e.g., ADA Standards of Care, ACC/AHA obesity guidelines). Attach everything at once rather than responding piecemeal to insurer requests.
Step Therapy and How to Navigate It
Some insurers require patients to try a lower-cost GLP-1 (often liraglutide) before they will approve a higher-cost one (tirzepatide or higher-dose semaglutide). This is called step therapy. If your prescriber believes the step therapy requirement is clinically inappropriate for your specific situation, they can submit a step therapy exception request documenting why the required first-step drug is contraindicated, would not be effective, or has already been tried. Most states have passed step therapy override laws that require insurers to grant exceptions in specific circumstances — check your state's insurance code or contact your state insurance commissioner's office.
Document every communication with your insurer about prior authorization — date, time, name of representative, phone number called, reference or claim number, and the substance of what was said. If a denial comes in writing, keep it. If an approval comes with conditions, keep that too. If you eventually need to escalate to a state insurance regulator or pursue litigation, this contemporaneous record is invaluable. Insurers sometimes do not follow their own procedures; documentation creates accountability.
Prior authorization for GLP-1 medications has been an evolving landscape. Some large commercial insurers have tightened criteria as the cost of covering these medications has grown; others have relaxed coverage in response to the cardiovascular outcome data from the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events and made it harder for insurers to categorize GLP-1s as “lifestyle” rather than medically necessary medications. Keep up with your plan's formulary and PA criteria — they may have changed since you last checked, in either direction.
Section 6 — Savings ProgramsManufacturer Coupons and Patient Assistance Programs
Moderate — Manufacturer programs are documented; specific eligibility terms change frequently and must be verified directlyBoth major GLP-1 manufacturers — Novo Nordisk and Eli Lilly — operate patient savings programs for their GLP-1 medications. These programs can dramatically reduce out-of-pocket costs for eligible patients, sometimes to zero. Understanding how they work, who qualifies, and where to apply is one of the most direct cost-reduction steps available.
Novo Nordisk: NovoCare Programs
Novo Nordisk operates NovoCare as its patient support and assistance platform covering Ozempic, Wegovy, Victoza, Saxenda, and other Novo products. NovoCare administers multiple programs with different eligibility criteria:
- Savings cards for commercially insured patients: Novo Nordisk has offered savings cards for Ozempic and Wegovy that cap patient monthly costs at a fixed low amount — historically $0 or $25 per month for eligible commercially insured patients. These cards function like a manufacturer coupon applied at the pharmacy. The terms have changed over time and vary by product.
- Patient assistance programs for uninsured or underinsured patients: For patients who are uninsured or whose income falls below specified thresholds, Novo Nordisk's patient assistance program provides medications at no or reduced cost. Income eligibility thresholds are periodically updated. Applications are submitted through NovoCare with income documentation.
- Medicare and Medicaid exclusion: Manufacturer savings cards cannot be used by patients enrolled in Medicare, Medicaid, or other federal healthcare programs under the federal Anti-Kickback Statute. This is not a Novo Nordisk policy choice — it is a federal legal requirement. Patients on Medicare or Medicaid need to explore separate options including Medicare Extra Help (Low Income Subsidy) and state pharmaceutical assistance programs.
Access NovoCare directly at novocare.com. Do not rely on third-party summaries (including this guide) for current eligibility terms, income thresholds, or program availability. Terms change, programs are modified, and some products may be added or removed from available programs. The authoritative source is Novo Nordisk's own patient assistance page.
Eli Lilly: Programs for Mounjaro and Zepbound
Eli Lilly operates patient assistance and savings programs for Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity). Lilly has offered savings cards with low monthly caps for commercially insured patients on both products. Lilly Cares (lillycares.com) provides access to Lilly's income-based patient assistance programs for uninsured or underinsured patients. As with Novo Nordisk's programs, Medicare and Medicaid patients are excluded from manufacturer savings cards under federal law.
Eli Lilly has also offered a direct-pay program through its LillyDirect platform, which allows patients to purchase certain Lilly products directly from the manufacturer at a set price, bypassing traditional pharmacy and insurance channels. This option has been particularly relevant for patients who do not have GLP-1 coverage under their insurance plan and do not qualify for income-based patient assistance. The terms and product availability of LillyDirect programs have evolved and should be verified directly at lillydirect.com.
Generic Liraglutide: No Manufacturer Savings Card, But Competitive GoodRx Pricing
Generic drugs do not have manufacturer savings cards — that is one of the reasons generic entry matters for patients. Manufacturers of branded drugs offer savings cards to maintain market share against generics; generic manufacturers compete on price directly. For generic liraglutide, the relevant comparison tool is GoodRx pricing across multiple pharmacies, not a savings card application. The good news is that generic competition tends to drive liraglutide prices down substantially from the branded price, so the absence of a savings card typically does not disadvantage the generic user.
Manufacturer savings programs, savings card terms, and income eligibility thresholds for patient assistance programs change frequently — sometimes annually, sometimes more often. Review your program eligibility and current terms at least once per year, and whenever you experience a change in insurance, income, or the medication you are prescribed. A program that was not available to you 12 months ago may be available now, or vice versa.
State Pharmaceutical Assistance Programs
Many states operate pharmaceutical assistance programs that provide additional subsidies for prescription medications, either for specific populations (elderly, low-income) or across the board. These programs vary significantly in scope, funding, and covered drugs. The National Conference of State Legislatures and the Partnership for Prescription Assistance maintain resources for locating state programs. For GLP-1 medications specifically, state program coverage is inconsistent — but it is worth checking if you are in a coverage gap and other options have been exhausted.
Frequently Asked Questions
Are Victoza and Saxenda the same drug?
Yes. Victoza and Saxenda are both brand names for liraglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. They are chemically identical molecules. The difference is the approved indication and the maximum dose: Victoza is approved for type 2 diabetes management at doses up to 1.8mg, while Saxenda is approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity, at doses up to 3mg. Because they are approved under different indications with different NDC codes, insurers price them differently, patient assistance programs differ, and pharmacy pricing differs. Generic liraglutide is now available — but price and coverage can still vary based on which indication the prescription documents.
When will generic semaglutide be available in the United States?
As of June 2026, generic injectable semaglutide has not reached the US market. Novo Nordisk holds multiple overlapping patents on Ozempic and Wegovy that extend into the late 2020s and early 2030s depending on the formulation. Compounded semaglutide from 503B outsourcing facilities was permitted during the FDA-declared shortage period, but the FDA has been issuing guidance on compounding allowance status as branded supply has recovered. Oral generic semaglutide (not injectable) became available in some Canadian provinces, but Canadian approval does not affect US market availability. The FDA shortage list and compounding allowance guidance are the most reliable sources to monitor for US availability updates.
Can I ask my doctor to write a prescription for a lower-cost GLP-1?
Yes, and this is one of the most legitimate cost-reduction strategies available to patients. Specifically: if you have both type 2 diabetes and obesity, your prescriber can document the diabetes indication for a liraglutide prescription — which may allow access to Victoza or generic liraglutide pricing rather than Saxenda pricing. The key legal and ethical principle is that you cannot misrepresent a diagnosis you do not have, but if both diagnoses are medically accurate, choosing which to document on the prescription is a legitimate clinical and economic decision. Similarly, asking your prescriber to write the generic name (liraglutide) rather than the brand name (Saxenda) when a generic is available is a standard cost-reduction practice that any physician should accommodate.
How does GoodRx work for GLP-1 medications?
GoodRx is a price comparison and coupon aggregator that negotiates discounted prices with pharmacies on behalf of users. For GLP-1 medications, GoodRx pricing can vary substantially between pharmacies — sometimes by hundreds of dollars for the same drug and dose. GoodRx works best for generic medications where multiple manufacturers have entered the market and pharmacy acquisition costs vary. For branded GLP-1s like Ozempic and Wegovy (where no generic exists as of June 2026), GoodRx may still provide a discount over retail, but the savings are typically more modest than for generics. GoodRx cannot be combined with insurance in most cases — you use one or the other for a given prescription. For generic liraglutide, GoodRx pricing is often competitive and worth checking before filling at any single pharmacy.
What are the Novo Nordisk and Eli Lilly patient assistance programs?
Novo Nordisk operates NovoCare, which provides patient assistance for its GLP-1 products including Ozempic and Wegovy. For commercially insured patients, Novo Nordisk has offered savings cards that cap the monthly patient cost at a low fixed amount (historically $0 or $25 for eligible patients). Income-based patient assistance programs provide medication at no or reduced cost to uninsured or underinsured patients who meet income criteria. Eli Lilly operates a similar program for its GLP-1 products Mounjaro and Zepbound. Savings card eligibility typically excludes patients on Medicare, Medicaid, or other federal programs. These programs change periodically — the most current terms are always available directly through NovoCare (novocare.com) and Lilly's patient support programs (lillycares.com). Do not rely on third-party summaries (including this one) for current eligibility terms.
What should I document for a GLP-1 prior authorization appeal?
If your insurer denies prior authorization for a GLP-1 medication, you have the right to appeal. The strongest appeals include: a physician letter documenting medical necessity with specific reference to your BMI, relevant comorbidities (type 2 diabetes, hypertension, cardiovascular disease, sleep apnea, NAFLD), and how those conditions are clinically linked to the requested medication; a weight history showing the chronicity and degree of obesity; documentation of prior treatment attempts and their outcomes (lifestyle programs, other weight loss medications); and the clinical guideline citations your prescriber is following. Keep records of every interaction with your insurer about the prior authorization — dates, names, claim or reference numbers, and the specific stated reason for denial. If the first-level appeal is denied, a second-level appeal or independent medical review is available in most states. Your state insurance commissioner's office can provide information about your appeal rights.